* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Monday, June 30, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Susquehanna Raises Penn Entertainment Inc. (PENN) Price Target. – Yahoo Finance

    Susquehanna Raises Price Target for Penn Entertainment Inc. (PENN)

    George Lopez is coming to Spokane – KXLY.com

    George Lopez is coming to Spokane – KXLY.com

    Netflix unveils Dallas immersive venue for fans of hit shows like ‘Squid Game,’ ‘Stranger Things’ – Houston Chronicle

    Step Inside Netflix’s New Dallas Immersive Experience Featuring Hits Like ‘Squid Game’ and ‘Stranger Things

    ‘Puttin’ on the Ritz’: Civic Players bring ‘Young Frankenstein’ to life – Yahoo

    Civic Players Deliver a Hilarious and Unforgettable Performance of ‘Young Frankenstein

    ‘Wheel of Fortune’: Amputee Wins $60,000 After Breaking Incredible ‘Curse’ – Hastings Tribune

    Wheel of Fortune’ Amputee Breaks Incredible ‘Curse’ to Win $60,000!

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    North Star Sports & Entertainment Network: Coming soon – KTTC News

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    New center coming to Mizzou will focus on energy research and technology – Columbia Missourian

    Mizzou Launches Innovative New Center Dedicated to Energy Research and Technology

    Mirrors in space and underwater curtains: can technology buy us enough time to save the Arctic ice caps? – The Guardian

    Can Technology Like Space Mirrors and Underwater Curtains Buy Us Time to Save the Arctic Ice Caps?

    Naples restaurant owner prepares for hurricane season with new flood technology – Fox4Now.com

    Naples restaurant owner prepares for hurricane season with new flood technology – Fox4Now.com

    Emerging Memory and Storage Technology Market Analysis Report 2025-2034 | AI and HPC Boom Fuels Surging Demand for Fast, Low-Power Memory Devices – Yahoo Finance

    How AI and HPC Are Driving Explosive Growth in Fast, Low-Power Memory Technologies Through 2034

    Ostin Technology (OST): Volatility’s Warning or Contrarian Opportunity? – AInvest

    Ostin Technology (OST): Navigating Market Volatility – Red Flag or Hidden Opportunity?

    St. Francis Medical Center brings advanced robotic surgery technology to Northeast Louisiana – KNOE

    St. Francis Medical Center brings advanced robotic surgery technology to Northeast Louisiana – KNOE

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Susquehanna Raises Penn Entertainment Inc. (PENN) Price Target. – Yahoo Finance

    Susquehanna Raises Price Target for Penn Entertainment Inc. (PENN)

    George Lopez is coming to Spokane – KXLY.com

    George Lopez is coming to Spokane – KXLY.com

    Netflix unveils Dallas immersive venue for fans of hit shows like ‘Squid Game,’ ‘Stranger Things’ – Houston Chronicle

    Step Inside Netflix’s New Dallas Immersive Experience Featuring Hits Like ‘Squid Game’ and ‘Stranger Things

    ‘Puttin’ on the Ritz’: Civic Players bring ‘Young Frankenstein’ to life – Yahoo

    Civic Players Deliver a Hilarious and Unforgettable Performance of ‘Young Frankenstein

    ‘Wheel of Fortune’: Amputee Wins $60,000 After Breaking Incredible ‘Curse’ – Hastings Tribune

    Wheel of Fortune’ Amputee Breaks Incredible ‘Curse’ to Win $60,000!

    North Star Sports & Entertainment Network: Coming soon – KTTC News

    North Star Sports & Entertainment Network: Coming soon – KTTC News

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    New center coming to Mizzou will focus on energy research and technology – Columbia Missourian

    Mizzou Launches Innovative New Center Dedicated to Energy Research and Technology

    Mirrors in space and underwater curtains: can technology buy us enough time to save the Arctic ice caps? – The Guardian

    Can Technology Like Space Mirrors and Underwater Curtains Buy Us Time to Save the Arctic Ice Caps?

    Naples restaurant owner prepares for hurricane season with new flood technology – Fox4Now.com

    Naples restaurant owner prepares for hurricane season with new flood technology – Fox4Now.com

    Emerging Memory and Storage Technology Market Analysis Report 2025-2034 | AI and HPC Boom Fuels Surging Demand for Fast, Low-Power Memory Devices – Yahoo Finance

    How AI and HPC Are Driving Explosive Growth in Fast, Low-Power Memory Technologies Through 2034

    Ostin Technology (OST): Volatility’s Warning or Contrarian Opportunity? – AInvest

    Ostin Technology (OST): Navigating Market Volatility – Red Flag or Hidden Opportunity?

    St. Francis Medical Center brings advanced robotic surgery technology to Northeast Louisiana – KNOE

    St. Francis Medical Center brings advanced robotic surgery technology to Northeast Louisiana – KNOE

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Business

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

July 10, 2024
in Business
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
Share on FacebookShare on Twitter

Author of the article:

GlobeNewswire

Published Jul 09, 2024  •  4 minute read

SPRING, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally available, brain penetrant, third generation RXR agonist compound which has been tested in early phase clinical trials in patients with Parkinson’s disease or cancers.   The presentation titled “The highly potent and selective RXR agonist compound IRX4204 is a potential treatment for normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD)” was delivered at the Federation of American Societies for Experimental Biology (FASEB) Seventh International Conference on Retinoids, being held in St. Paul, Minnesota, USA. The presentation was authored by Vidyasagar Vuligonda, Ph.D., Chief Science Officer of the company and inventor of IRX4204, and Martin E. Sanders, M.D., the company’s Chief Executive Officer.

Advertisement 2

This advertisement has not loaded yet, but your article continues below.

Financial Post

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

Exclusive articles from Barbara Shecter, Joe O’Connor, Gabriel Friedman, Victoria Wells and others.Daily content from Financial Times, the world’s leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.

REGISTER / SIGN IN TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.

Sign In or Create an Account

or

Article content

Normal aging-related neurodegeneration has been reported to be substantially related to chronic low-grade inflammation in the brain, so called neuro-inflammaging. Neuro-inflammaging results in chronic loss of myelinated nerve fibers, causing disruption of functional neuroelectrical connections between neurons in various parts of the brain. Chronic neuro-inflammaging eventually leads to death of neurons. These neurodegenerative processes produce loss of memory and cognitive functions, and other functional disabilities in patients with normal brain aging, and in diverse types of neurological conditions including PD, and AD.

Neuro-inflammaging is related to imbalance of immunosuppressive T-regulatory cells (Treg) with pro-inflammatory cytokine interleukin-17 (IL-17) overproducing T-cells (Th17) in the brain. Neuro-inflammaging also is related to overactivity of brain microglia, which produce the pro-inflammatory cytokine interleukin-6 (IL-6), and other pro-inflammatory factors.

Parkinson’s disease (PD) and Alzheimer’s disease (AD) brains manifest similar neuro-inflammaging pathologies to those observed in normal brain aging, but also have distinct pathologies related to deposition of abnormal misfolded proteins such as alpha synuclein in PD, and beta amyloid in AD. It is generally accepted within the neurodegenerative diseases research community that neuro-inflammaging establishes an at-risk environment within the brain, that may increase vulnerability for development of PD, AD, and other neurodegenerative diseases.

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Article content

Advertisement 3

This advertisement has not loaded yet, but your article continues below.

Article content

The presented studies showed that IRX4204 promotes differentiation and growth of immunosuppressive human Tregs, and inhibits differentiation of pro-inflammatory human Th17 cells, while reducing production of IL-17. IRX4204 also inhibits production by microglia of IL-6 and other pro-inflammatory factors. In addition, IRX4204 promotes differentiation and growth of myelin-producing oligodendrocytes in vitro and promotes myelinated nerve fiber protection and repair (remyelination) in mouse models of demyelination. IRX4204 demonstrated direct beneficial effects alone, and additively in combination with insulin, or thyroid hormone on cortical neurons in vitro, promoting neurite outgrowth, a neuro-reparative mechanism by which damaged neurons may re-establish function-preserving connections with other neurons. These findings support the potential for IRX4204 protecting against or even reversing neuro-inflammaging-induced chronic loss of myelinated nerve fibers and neuronal damage in normal brain aging and neurodegenerative diseases.

Advertisement 4

This advertisement has not loaded yet, but your article continues below.

Article content

Further demonstration of IRX4204 beneficial effects in neurodegeneration was provided by in vivo studies in rodent models of PD, and AD. IRX4204 effectively reduced motor deficits in a rat PD model while increasing dopaminergic neuron survival in the rat brains. In a transgenic beta amyloid mouse model of AD, IRX4204 decreased deposition of new beta amyloid in the mouse brains while preserving memory functions in the mice.

IRX4204 has demonstrated safety and tolerability of oral dosing in phase I and II clinical trials in 85 patients with various cancers and 15 patients with PD for up to 20 months of continuous treatment. In PD patients, IRX4204 demonstrated brain penetrance, and improvement of motor functions in 13 of 15 patients in open label assessments. The company is planning to initiate a placebo-controlled phase II clinical trial of IRX4204 in Parkinson’s disease patients in Q4 of 2024, to further demonstrate safety and efficacy in PD patients.

Dr. Vuligonda stated, “Our results identify a new approach to potentially slowing or reversing the neurodegeneration of normal aging, as well as treating the pathologic conditions of Parkinson’s disease and Alzheimer’s disease, which cause seriously disabling chronic decline of cognitive and other functional abilities.”  

Advertisement 5

This advertisement has not loaded yet, but your article continues below.

Article content

Dr. Sanders stated, “IRX4204 has been safe and well tolerated in patients and has potential to be an effective monotherapy for prevention or treatment of debilitating neurologic manifestations associated with normal aging, Parkinson’s disease, Alzheimer’s disease and other neurologic conditions.   In addition, IRX4204 provides opportunities for future development of combination treatments with even greater efficacy for these conditions, by administering IRX4204 with other generally well-tolerated and already available agents, such as insulin, GLP-1 agonists, other neurotrophic factors, thyroid hormone, or anti-beta amyloid monoclonal antibodies. We believe multi-agent combination treatments including IRX4204 will enable development of well tolerated, highly effective preventative and therapeutic interventions for diverse types of neurodegenerative diseases.”

About Io Therapeutics:   Io Therapeutics, Inc. is a privately held company headquartered in Spring, Texas.   More information on Io Therapeutics and its product development programs is available on the company’s web site: www.io-therapeutics.com 

Forward Looking Statements: This news release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.

Contact:

[email protected]


Article content

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Financial Post – https://financialpost.com/globe-newswire/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-companys-phase-ii-clinical-development-stage-highly-selective-third-generation-rxr-nuclear-receptor-agonist-compound-supporting-i

Tags: businessDiseaseTherapeutics
Previous Post

NexGold Mining Completes Name Change and Consolidation

Next Post

Ex-Morgan Stanley Banker’s Fund Raises $3.4 Billion, Beating Asia Rivals

New center coming to Mizzou will focus on energy research and technology – Columbia Missourian

Mizzou Launches Innovative New Center Dedicated to Energy Research and Technology

June 30, 2025
Atlanta Dream Dealt Concerning Loss During Liberty Game – Yahoo Sports

Atlanta Dream Faces Crushing Defeat in Thrilling Liberty Clash

June 30, 2025
More than 1,800 National Science Foundation workers abruptly kicked out of agency headquarters – Space

Over 1,800 National Science Foundation Employees Suddenly Evicted from Agency Headquarters

June 30, 2025
Scientists Retrace 30,000-Year-Old Sea Voyage, in a Hollowed-Out Log – The New York Times

Scientists Successfully Recreate Epic 30,000-Year-Old Sea Voyage in a Hollowed-Out Log

June 30, 2025
Tom Brady Ditches Sneakers Lifestyle For Jeff Bezos & Lauren Sánchez’s Wedding – Yahoo

Tom Brady Swaps Sneakers Lifestyle for Glamorous Jeff Bezos and Lauren Sánchez Wedding Celebration

June 30, 2025
Chivu Confirms France Star Fit For Inter Milan Vs Fluminense Club World Cup Clash – Yahoo Sports

Chivu Confirms France Star Ready for Inter Milan’s Club World Cup Showdown Against Fluminense

June 30, 2025
Trump’s tariffs damage the US economy more if they drive investors away from American assets – Peterson Institute for International Economics

How Trump’s Tariffs Could Backfire by Driving Investors Away from American Assets

June 30, 2025
Surprising New Study Links Daytime Napping to Hidden Health Risks – Prevention

Surprising New Research Uncovers Hidden Health Risks of Daytime Napping

June 30, 2025
The 1975’s Matty Healy Says ‘We Don’t Need More Politics’ at Glastonbury – Variety

The 1975’s Matty Healy Declares “We Don’t Need More Politics” at Glastonbury

June 30, 2025
Mirrors in space and underwater curtains: can technology buy us enough time to save the Arctic ice caps? – The Guardian

Can Technology Like Space Mirrors and Underwater Curtains Buy Us Time to Save the Arctic Ice Caps?

June 29, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (700)
  • Economy (724)
  • Entertainment (21,613)
  • General (15,630)
  • Health (9,763)
  • Lifestyle (729)
  • News (22,149)
  • People (725)
  • Politics (730)
  • Science (15,941)
  • Sports (21,221)
  • Technology (15,709)
  • World (704)

Recent News

New center coming to Mizzou will focus on energy research and technology – Columbia Missourian

Mizzou Launches Innovative New Center Dedicated to Energy Research and Technology

June 30, 2025
Atlanta Dream Dealt Concerning Loss During Liberty Game – Yahoo Sports

Atlanta Dream Faces Crushing Defeat in Thrilling Liberty Clash

June 30, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version